Encounter frequency and serum glucose level, blood pressure, and cholesterol level control in patients with diabetes mellitus

Archives of Internal Medicine

Volumn 171, Issue 17, 2011, Pages 1542-1550

  Morrison, Fritha ^a   Shubina, Maria ^a   Turchin, Alexander ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b PARTNERS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONSULTATION; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT CARE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; OFFICE VISITS; PHYSICIANS, PRIMARY CARE; PRIMARY HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 80053355283     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2011.400     Document Type: Article

References (62)

1. 1C criteria in the U.S. population in 1988-2006. Diabetes Care. 2010;33(3):562-568.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27 (5):1047-1053. (Pubitemid 38579764)
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-986.
4. Nathan DM, Cleary PA, Backlund JY, et al Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. (Pubitemid 41817713)
5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose controlwith sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352(9131):837-853.
6. Goldberg RB, Mellies MJ, Sacks FM, et al The Care Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98 (23):2513-2519. (Pubitemid 29001188)
7. Pyürälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20(4):614-620. (Pubitemid 27143424)
8. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317(7160):703-713.
9. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care. 2006;29(3):531-537. (Pubitemid 44115349)
10. Ong KL, Cheung BM, Wong LY, Wat NM, Tan KC, Lam KS. Prevalence, treatment, and control of diagnosed diabetes in the U.S. National Health and Nutrition Examination Survey 1999-2004. Ann Epidemiol. 2008;18(3):222-229.
11. Hong CS, Atlas SJ, Chang Y, et al. Relationship between patient panel characteristics and primary care physician clinical performance rankings. JAMA. 2010; 304(10):1107-1113.
12. Turchin A, Goldberg SI, Shubina M, Einbinder JS, Conlin PR. Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus. Hypertension. 2010;56(1):68-74.
13. Guthmann R, Davis N, Brown M, Elizondo J. Visit frequency and hypertension. JClin Hypertens (Greenwich). 2005;7(6):327-332.
14. American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care. 2010;33(suppl 1):S11-S61.
15. Nathan DM, Buse JB, Davidson MB, et al American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1): 193-203.
16. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
17. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 2000;23(suppl 1):S32-S42.
18. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T; Agency for Health Care Policy and Research. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. JAMA. 1997;278(21): 1759-1766. (Pubitemid 27510076)
19. Turchin A, Shubina M, Chodos AH, Einbinder JS, Pendergrass ML. Effect of board certification on antihypertensive treatment intensification in patients with diabetes mellitus. Circulation. 2008;117(5):623-628.
20. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339(27):1957-1963. (Pubitemid 29024127)
21. Turchin A, Kolatkar NS, Grant RW, Makhni EC, Pendergrass ML, Einbinder JS. Using regular expressions to abstract blood pressure and treatment intensification information from the text of physician notes. J AmMed Inform Assoc. 2006; 13(6):691-695. (Pubitemid 44648764)
22. Turchin A, Shubina M, Breydo E, Pendergrass ML, Einbinder JS. Comparison of information content of structured and narrative text data sources on the example of medication intensification. J Am Med Inform Assoc. 2009;16(3):362-370.
23. Lin DY. Cox regression analysis of multivariate failure time data: the marginal approach. Stat Med. 1994;13(21):2233-2247. (Pubitemid 24343234)
24. Greenland S. Principles of multilevel modelling. Int J Epidemiol. 2000;29(1):158-167. (Pubitemid 30119722)
25. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika. 1986;73(3):751-754.
26. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75(4):800-802.
27. Goodman LS, Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th ed. New York, NY: McGraw-Hill Professional; 2011.
28. McPhee S, Papadakis M, Rabow MW. Current Medical Diagnosis & Treatment. New York, NY: McGraw-Hill Medical; 2011.
29. Simonson DC, Kourides IA, Feinglos M, Shamoon H, Fischette CT; The Glipizide Gastrointestinal Therapeutic System Study Group. Efficacy, safety, and doseresponse characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care. 1997;20(4):597-606. (Pubitemid 27143421)
30. Rosenstock J, Hassman DR, Madder RD, et al Repaglinide Versus Nateglinide Comparison Study Group. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care. 2004;27(6):1265-1270. (Pubitemid 38679968)
31. Marre M, Shaw J, Brändle M, et al; LEAD-1 SU study group. Liraglutide, a oncedaily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268-278.
32. Russell-Jones D, Vaag A, Schmitz O, et al; Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009; 52(10):2046-2055.
33. Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 2006;29(12):2632-2637. (Pubitemid 44912190)
34. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R; CV181-040 Investigators. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009; 63(9):1395-1406.
35. Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med. 2001;111(1):10-17. (Pubitemid 32635256)
36. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695-1702. (Pubitemid 30196209)
37. Donnelly R, Elliott HL, Meredith PA, Kelman AW, Reid JL. Nifedipine: individual responses and concentration-effect relationships. Hypertension. 1988;12(4): 443-449.
38. Donnelly R, Elliott HL, Meredith PA, Reid JL. Concentration-effect relationships and individual responses to doxazosin in essential hypertension. Br J Clin Pharmacol. 1989;28(5):517-526. (Pubitemid 19273598)
39. Donnelly R, Meredith PA, Elliott HL, Reid JL. Kinetic-dynamic relations and individual responses to enalapril. Hypertension. 1990;15(3):301-309. (Pubitemid 20097458)
40. Michelson EL, Frishman WH, Lewis JE, et al. Multicenter clinical evaluation of long-term efficacy and safety of labetalol in treatment of hypertension. Am J Med. 1983;75(4A):68-80. (Pubitemid 13022749)
41. Pool JL, Guthrie RM, Littlejohn TW III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.AmJ Hypertens. 1998;11(4, pt 1):462-470. (Pubitemid 28231459)
42. van Brummelen P, Man in 't Veld AJ, Schalekamp MA. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders. Clin Pharmacol Ther. 1980;27(3):328-336. (Pubitemid 10099119)
43. Bakker-Arkema RG, Davidson MH, Goldstein RJ, et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275(2):128-133. (Pubitemid 26022591)
44. Patel NC, Crismon ML, Miller AL, Johnsrud MT. Drug adherence: effects of decreased visit frequency on adherence to clozapine therapy. Pharmacotherapy. 2005;25(9):1242-1247. (Pubitemid 41242581)
45. Wannamaker BB, Morton WA Jr, Gross AJ, Saunders S. Improvement in antiepileptic drug levels following reduction of intervals between clinic visits. Epilepsia. 1980;21(2):155-162. (Pubitemid 10125585)
46. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-1760. (Pubitemid 351697950)
47. Julius S, Kjeldsen SE, Weber M, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426): 2022-2031. (Pubitemid 38781102)
48. Cannon CP, Braunwald E, McCabe CH, et al Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495-1504. (Pubitemid 38477774)
49. Colhoun HM, Betteridge DJ, Durrington PN, et al CARDS Investigators. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetologia. 2005;48(12):2482-2485. (Pubitemid 41738211)
50. Colhoun HM, Betteridge DJ, Durrington PN, et al; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-696. (Pubitemid 39140624)
51. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615-1622. (Pubitemid 28248586)
52. Shepherd J, Cobbe SM, Ford I, et al West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333(20):1301-1307.
53. Østbye T, Yarnall KS, Krause KM, Pollak KI, Gradison M, Michener JL. Is there time for management of patients with chronic diseases in primary care? Ann Fam Med. 2005;3(3):209-214. (Pubitemid 40806713)
54. Bodenheimer T. Primary care-will it survive? N Engl J Med. 2006;355(9):861-864.
55. Hauer KE, Durning SJ, Kernan WN, et al. Factors associated with medical students'career choices regarding internal medicine. JAMA. 2008;300(10):1154- 1164.
56. Lee TH, Bodenheimer T, Goroll AH, Starfield B, Treadway K. Perspective roundtable: redesigning primary care. N Engl J Med. 2008;359(20):e24. doi:10.1056 /NEJMp0809050.
57. Denver EA, Barnard M, Woolfson RG, Earle KA. Management of uncontrolled hypertension in a nurse-led clinic compared with conventional care for patients with type 2 diabetes. Diabetes Care. 2003;26(8):2256-2260. (Pubitemid 36993309)
58. New JP, Mason JM, Freemantle N, et al. Specialist nurse-led intervention to treat and control hypertension and hyperlipidemia in diabetes (SPLINT): a randomized controlled trial. Diabetes Care. 2003;26(8):2250-2255. (Pubitemid 36993308)
59. Taylor CB, Miller NH, Reilly KR, et al. Evaluation of a nurse-care management system to improve outcomes in patients with complicated diabetes. Diabetes Care. 2003;26(4):1058-1063. (Pubitemid 36929248)
60. Vivian EM. Improving blood pressure control in a pharmacist-managed hypertension clinic. Pharmacotherapy. 2002;22(12):1533-1540. (Pubitemid 35429949)
61. Wick A, Koller MT. Views of patients and physicians on follow-up visits: results from a cross-sectional study in Swiss primary care. Swiss Med Wkly. 2005; 135(9-10):139-144.
62. Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ. 2004;328(7433):204-209.